BRIEF published on 09/18/2024 at 07:35, 11 days 5 hours ago Nicox Announces Approval of ZERVIATE in China China Ophthalmology Nicox ZERVIATE Ocumension
PRESS RELEASE published on 09/18/2024 at 07:30, 11 days 5 hours ago Nicox Announces Approval of ZERVIATE in China Nicox announces approval of ZERVIATE in China by partner Ocumension Therapeutics for ocular itching, adding royalty revenue stream. Launch expected to boost market penetration China Approval Nicox ZERVIATE Ocular Itching
BRIEF published on 09/04/2024 at 07:35, 25 days 5 hours ago Nicox Appoints Christine Placet as Director; Michele Garufi Retires from Board of Directors Board Of Directors Ophthalmology Christine Placet Nicox Michele Garufi
PRESS RELEASE published on 09/04/2024 at 07:30, 25 days 5 hours ago Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Nicox appoints Christine Placet to Board of Directors as Michele Garufi steps down after over 25 years. Entire Nicox Board renewed for strategic direction support Board Of Directors Biotech Industry Christine Placet Nicox Michele Garufi
BRIEF published on 07/19/2024 at 07:35, 2 months 10 days ago Nicox: Participation in upcoming conferences Conférences 2024 Investments Ophthalmology Nicox
PRESS RELEASE published on 07/19/2024 at 07:30, 2 months 10 days ago Nicox announces attendance at upcoming conferences Nicox announces attendance at upcoming international conferences, including H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and AAO 2024 Clinical Development International Conférences Ophthalmology Nicox
BRIEF published on 07/18/2024 at 07:35, 2 months 11 days ago Nicox Provides Second Quarter 2024 Update Q2 2024 Financial Update Ophthalmology Nicox NCX 470
PRESS RELEASE published on 07/18/2024 at 07:30, 2 months 11 days ago Nicox Provides Second Quarter 2024 Update Nicox reports €1.6M revenue & €7.8M cash for Q2 2024, extending funds until Feb 2025. Focus on NCX 470 development & Denali trial progress. New Board members appointed Revenue Cash Position Nicox NCX 470 Denali Trial
BRIEF published on 07/16/2024 at 07:35, 2 months 13 days ago Nicox appoints Damian Marron Chairman of the Board of Directors Board Of Directors Ophthalmology Nicox Marc Le Bozec Damian Brown
PRESS RELEASE published on 07/16/2024 at 07:30, 2 months 13 days ago Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Nicox appoints Damian Marron as Chair of the Board and Marc Le Bozec as Director. Experienced leaders join Nicox Board, Labbe and Kaplan step down. Strategic shift in leadership Board Of Directors Healthcare Nicox Damian Marron Marc Le Bozec
Published on 09/28/2024 at 02:06, 1 day 11 hours ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 11 hours ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 13 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 23 hours 24 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 14 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 15 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 18 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 18 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 19 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 19 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 19 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 19 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024